secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0000950170-23-040151
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma Q2 net loss $17.4M; FDA aligns on Phase 2 dose for PC14586
---------------------------------------------------------------------

- Cash, equivalents & marketable securities $218.8M as of June 30, 2023, down from $277.4M a year ago.
- Net loss for six months ended June 30, 2023 was $36.6M vs. $35.7M in same period 2022.
- R&D expenses rose to $28.9M for six months, driven by headcount and clinical costs for PC14586.
- FDA alignment obtained on recommended Phase 2 dose and key elements of registrational trial; Phase 1 data update expected 2H 2023.
- Appointed Dr. Masha Poyurovsky as Vice President of Biology; ongoing combination arm with KEYTRUDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000095017023040151/0000950170-23-040151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000095017023040151/pmvp-20230809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer